(Reuters) — Pfizer Inc and its partner BioNTech Se plan to give volunteers who received a placebo in its COVID-19 vaccine trial an option to receive a first dose of the vaccine by March 1, 2021, while staying within the study.
The trial’s Vaccine Transition Option allows all participants aged 16 or older the choice to discover whether they were given the placebo, “and for participants who learn they received the placebo, to have the option to receive the investigational vaccine while staying in the study,” the companies said on their website for trial participants.
The U.S. Food and Drug Administration and a panel of its outside advisers have expressed concerns over Pfizer’s “unblinding” plan, saying it could make it harder to continue collecting data on safety and effectiveness needed to win full FDA approval of the vaccine.
Latest coronavirus headlines
- Tennis players in lockdown after positive virus cases in Australia
- Pharmacist discusses challenges of delivering vaccine to remote areas of Alaska
- California Rep. Lou Correa tests positive for coronavirus
- Rhode Island doctor accused of ‘recklessly’ exposing patients, staff to COVID-19
- Dallas County detects its 1st known case of COVID-19 variant
Trial participants who received the placebo will have two doses of the investigational vaccine reserved for them within the study, the companies said on the website.
“The study doctor will follow the latest guidance from the U.S. Centers for Disease Control and Prevention and their local health authorities to offer the Vaccine Transition Option to participants in a prioritized manner,” the companies said.
© Copyright Thomson Reuters 2021